Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 3:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: PID Clear all
Completed Phase 3 Interventional Results available

Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)

NCT01814800
View directory record Official record
Conditions
Primary Immune Deficiency Disorder
Interventions
RI-002
Biological
Lead sponsor
ADMA Biologics, Inc.
Industry
Eligibility
2 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
9
States / cities
Cenntennial, Colorado • North Palm Beach, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 4 Interventional Results available

A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency

NCT01289847
View directory record Official record
Conditions
Primary Immune Deficiency Disorders, Common Variable Immunodeficiency, X-linked Agammaglobulinemia, Hyper-IgM Syndrome, Wiskott-Aldrich Syndrome
Interventions
Gammaplex
Biological
Lead sponsor
Bio Products Laboratory
Other
Eligibility
2 Years to 16 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Irvine, California • Los Angeles, California • Centennial, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Feasibility Study of PID Versus MPC and HMS

NCT01987206
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
MPC control algorithm, PID control algorithm
Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects

NCT03277313
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
HYQVIA
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
2 Years to 15 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
19
States / cities
Birmingham, Alabama • Hartford, Connecticut • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 2Phase 3 Interventional

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

NCT05755035
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
TAK-881, HYQVIA
Biological
Lead sponsor
Takeda
Industry
Eligibility
2 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
15
States / cities
Irvine, California • Walnut Creek, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects

NCT00546871
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
Immune Globulin Intravenous (Human), 10%
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
24 Months and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
9
States / cities
Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 7, 2026, 3:15 AM EDT
Active, not recruiting Not applicable Interventional

Technology Based Community Health Nursing(TECH-N) to Prevent Recurrent STIs After PID II

NCT03828994
View directory record Official record
Conditions
Pelvic Inflammatory Disease
Interventions
Tech-PN
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
13 Years to 25 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 7, 2026, 3:15 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

NCT04554914
View directory record Official record
Conditions
Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma
Interventions
Tabelecleucel
Biological
Lead sponsor
Pierre Fabre Medicament
Industry
Eligibility
Not listed
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
23
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Controlled Clinical Trial of Supplemental Oxygen for the Prevention of Post-Cesarean Infectious Morbidity

NCT00603603
View directory record Official record
Conditions
Infection; Cesarean Section, Surgical Wound Infection, Endometritis
Interventions
80% inhaled oxygen via non-rebreather mask, 30% inhaled oxygen via nasal cannula
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 50 Years · Female only
Enrollment
606 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vaginal Cleansing Before Cesarean Delivery to Reduce Infection

NCT02495753
View directory record Official record
Conditions
Complications; Cesarean Section
Interventions
Vaginal Cleansing, Abdominal Cleansing
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Female only
Enrollment
608 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Sep 7, 2026, 3:15 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Studies of Disorders With Increased Susceptibility to Fungal Infections

NCT01222741
View directory record Official record
Conditions
Fungal Infections, Primary Immune Deficiencies
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 85 Years
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases

NCT01012323
View directory record Official record
Conditions
Primary Immunodeficiency Diseases
Interventions
NewGam
Biological
Lead sponsor
Octapharma
Industry
Eligibility
2 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
7
States / cities
Irvine, California • Centennial, Colorado • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 7, 2026, 3:15 AM EDT
Terminated Not applicable Interventional Results available

Vaginal Cleansing at Cesarean Delivery to Reduce Infection: A Randomized, Controlled Trial

NCT00386477
View directory record Official record
Conditions
Cesarean Section, Endometritis, Surgical Wound Infection
Interventions
Vaginal cleansing before cesarean delivery
Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 7, 2010 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID

NCT02810444
View directory record Official record
Conditions
Primary Immunodeficiency Disease
Interventions
IgG Next Generation (BT595)
Biological
Lead sponsor
Biotest
Industry
Eligibility
2 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Centennial, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

NCT00322556
View directory record Official record
Conditions
Agammaglobulinemia, IgG Deficiency, Common Variable Immunodeficiency
Interventions
Immunoglobulins Intravenous (Human)
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
4 Years to 71 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
10
States / cities
Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Sep 7, 2026, 3:15 AM EDT
Active, not recruiting Phase 3 Interventional

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)

NCT04944979
View directory record Official record
Conditions
Primary Immunodeficiency Disease
Interventions
Kedrion IVIG 10%
Biological
Lead sponsor
Kedrion S.p.A.
Industry
Eligibility
2 Years to 16 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
8
States / cities
San Francisco, California • Centennial, Colorado • St. Petersburg, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Not applicable Interventional

Improving Primary Care Follow-up for Patients With Pelvic Inflammatory Disease

NCT01299259
View directory record Official record
Conditions
Pelvic Inflammatory Disease
Interventions
Text Message Reminders
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
15 Years and older · Female only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

MOCHI: An RCT of Mindfulness as Treatment for Chronic Pelvic Pain in AD Women

NCT04104542
View directory record Official record
Conditions
Chronic Pelvic Pain, Depression, Inflammation Pelvic
Interventions
Mindfulness based stress reduction, Healthy Lifestyle
Behavioral
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
21 Years to 50 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 2 Interventional Results available

Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer

NCT04246489
View directory record Official record
Conditions
Uterine Cervical Neoplasms
Interventions
Bintrafusp alfa
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas • Stanford, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Not applicable Interventional Results available

Effect of Gain on Closed-Loop Insulin

NCT02065895
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
HIGH error, NO error, LOW error
Device
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

STRIPES Study: Study To Reduce Infection Post cEsarean Section

NCT02402907
View directory record Official record
Conditions
Chlorhexidine Gluconate Cloths, Infection; Cesarean Section, Infectious Morbidity, Surgical Site Infections, Endometritis
Interventions
2% chlorhexidine gluconate (CHG) cloth, Placebo cloth
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
1,356 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 8, 2020 · Synced Sep 7, 2026, 3:15 AM EDT
Not listed No phase listed Observational

A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products

NCT03037359
View directory record Official record
Conditions
Primary Immune Deficiency Disorder
Interventions
Bivigam, Other
Biological
Lead sponsor
ADMA Biologics, Inc.
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
17
States / cities
Carpinteria, California • Walnut Creek, California • Centennial, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Sep 7, 2026, 3:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

The Pharmacokinetics of Azithromycin Prophylaxis for Cesarean Delivery

NCT01464840
View directory record Official record
Conditions
Endometritis
Interventions
Azithromycin
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)

NCT00538915
View directory record Official record
Conditions
Primary Immune Deficiency Disorders (PIDD)
Interventions
Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]
Biological
Lead sponsor
ADMA Biologics, Inc.
Industry
Eligibility
6 Years to 75 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Sep 7, 2026, 3:15 AM EDT